FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2335282954> ?p ?o ?g. }

• W2335282954 endingPage "30" @default.
• W2335282954 startingPage "26" @default.
• W2335282954 abstract "Aim: To analyze expression of miRNA in human breast cancer cells, sensitive and resistant to cisplatin and doxorubicin, and to explore possible modification of drug sensitivity via treatment of cells with 5-azacytidine (5-aza), a demethylating agent. Materials and Methods: The study was performed on wild-type MCF-7 cell line (MCF-7/S) and its two sublines MCF-7/Dox and MCF-7/DDP resistant to doxorubicin and cisplatin, respectively. Cells were treated with 5-aza, cisplatin, doxorubicin and their combinations. Relative expression levels of miRNA-221, -200b, -320a, -10b, -34a, -122 and -29b were examined, using qRT-PCR. The MTT assay was used to monitor cell viability. Results: We compared miRNA expression profiles in MCF-7/S and drug resistant MCF-7/Dox and MCF-7/DDP cells. Changes of miRNA-221, -200b, -320a, -10b, -34a, -122 and -29b were observed in both resistant cell lines. The most significant differences were found for miRNA-200b (decreased in 50.0 ± 2.6 and 63.0 ± 3.1 times for MCF-7/Dox and MCF7/DDP cells, respectively) and for oncogenic miRNA-221 levels (increase in 62.0 ± 5.7 times for MCF-7/Dox and 83.8 ± 7.2 times for MCF-7/DDP cells). 5-aza treatment caused an increase of miRNA-10b, -122, -200b levels in MCF-7/S cells, miRNA-34a, -10b, -122, -200b and -320a levels in MCF-7/Dox cells and miRNA-34a, -10b, -200b and -320a levels in MCF-7/DDP cells. Pretreatment of all studied lines with 5-aza resulted in the increase of their sensitivity to studied cytostatics. In particular, the IC50 of doxorubicin decreased by 2-, 4- and 3-fold for cell lines MCF-7/S, MCF-7/Dox and MCF-7/DDP cells, respectively, and IC50 of cisplatin in studied cultures decreased by 3-, 2- and 1.5-fold, respectively. Conclusions: It was shown that use of 5-aza can modify sensitivity of breast cancer cells to cytotoxic drugs not only by it’s demetylation effect, but also by changes in expression of miRNAs, involved in cell proliferation, migration and drug resistance development." @default.
• W2335282954 created "2016-06-24" @default.
• W2335282954 creator A5049651100 @default.
• W2335282954 creator A5058327743 @default.
• W2335282954 creator A5081677452 @default.
• W2335282954 date "2016-03-22" @default.
• W2335282954 modified "2023-09-26" @default.
• W2335282954 title "EFFECT OF 5-AZACYTIDINE ON miRNA EXPRESSION IN HUMAN BREAST CANCER CELLS WITH DIFFERENT SENSITIVITY TO CYTOSTATICS" @default.
• W2335282954 doi "https://doi.org/10.31768/2312-8852.2016.38(1):26-30" @default.
• W2335282954 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27031715" @default.
• W2335282954 hasPublicationYear "2016" @default.
• W2335282954 type Work @default.
• W2335282954 sameAs 2335282954 @default.
• W2335282954 citedByCount "4" @default.
• W2335282954 countsByYear W23352829542017 @default.
• W2335282954 countsByYear W23352829542021 @default.
• W2335282954 countsByYear W23352829542023 @default.
• W2335282954 crossrefType "journal-article" @default.
• W2335282954 hasAuthorship W2335282954A5049651100 @default.
• W2335282954 hasAuthorship W2335282954A5058327743 @default.
• W2335282954 hasAuthorship W2335282954A5081677452 @default.
• W2335282954 hasBestOaLocation W23352829542 @default.
• W2335282954 hasConcept C104317684 @default.
• W2335282954 hasConcept C109316439 @default.
• W2335282954 hasConcept C109541995 @default.
• W2335282954 hasConcept C121608353 @default.
• W2335282954 hasConcept C126322002 @default.
• W2335282954 hasConcept C145059251 @default.
• W2335282954 hasConcept C1491633281 @default.
• W2335282954 hasConcept C150194340 @default.
• W2335282954 hasConcept C153911025 @default.
• W2335282954 hasConcept C185592680 @default.
• W2335282954 hasConcept C190727270 @default.
• W2335282954 hasConcept C202751555 @default.
• W2335282954 hasConcept C2776694085 @default.
• W2335282954 hasConcept C2778239845 @default.
• W2335282954 hasConcept C2779277951 @default.
• W2335282954 hasConcept C2780783641 @default.
• W2335282954 hasConcept C2781303535 @default.
• W2335282954 hasConcept C2994423619 @default.
• W2335282954 hasConcept C502942594 @default.
• W2335282954 hasConcept C53227056 @default.
• W2335282954 hasConcept C54355233 @default.
• W2335282954 hasConcept C55493867 @default.
• W2335282954 hasConcept C62112901 @default.
• W2335282954 hasConcept C71924100 @default.
• W2335282954 hasConcept C81885089 @default.
• W2335282954 hasConcept C86803240 @default.
• W2335282954 hasConcept C96232424 @default.
• W2335282954 hasConcept C98274493 @default.
• W2335282954 hasConceptScore W2335282954C104317684 @default.
• W2335282954 hasConceptScore W2335282954C109316439 @default.
• W2335282954 hasConceptScore W2335282954C109541995 @default.
• W2335282954 hasConceptScore W2335282954C121608353 @default.
• W2335282954 hasConceptScore W2335282954C126322002 @default.
• W2335282954 hasConceptScore W2335282954C145059251 @default.
• W2335282954 hasConceptScore W2335282954C1491633281 @default.
• W2335282954 hasConceptScore W2335282954C150194340 @default.
• W2335282954 hasConceptScore W2335282954C153911025 @default.
• W2335282954 hasConceptScore W2335282954C185592680 @default.
• W2335282954 hasConceptScore W2335282954C190727270 @default.
• W2335282954 hasConceptScore W2335282954C202751555 @default.
• W2335282954 hasConceptScore W2335282954C2776694085 @default.
• W2335282954 hasConceptScore W2335282954C2778239845 @default.
• W2335282954 hasConceptScore W2335282954C2779277951 @default.
• W2335282954 hasConceptScore W2335282954C2780783641 @default.
• W2335282954 hasConceptScore W2335282954C2781303535 @default.
• W2335282954 hasConceptScore W2335282954C2994423619 @default.
• W2335282954 hasConceptScore W2335282954C502942594 @default.
• W2335282954 hasConceptScore W2335282954C53227056 @default.
• W2335282954 hasConceptScore W2335282954C54355233 @default.
• W2335282954 hasConceptScore W2335282954C55493867 @default.
• W2335282954 hasConceptScore W2335282954C62112901 @default.
• W2335282954 hasConceptScore W2335282954C71924100 @default.
• W2335282954 hasConceptScore W2335282954C81885089 @default.
• W2335282954 hasConceptScore W2335282954C86803240 @default.
• W2335282954 hasConceptScore W2335282954C96232424 @default.
• W2335282954 hasConceptScore W2335282954C98274493 @default.
• W2335282954 hasIssue "1" @default.
• W2335282954 hasLocation W23352829541 @default.
• W2335282954 hasLocation W23352829542 @default.
• W2335282954 hasLocation W23352829543 @default.
• W2335282954 hasOpenAccess W2335282954 @default.
• W2335282954 hasPrimaryLocation W23352829541 @default.
• W2335282954 hasRelatedWork W1846905574 @default.
• W2335282954 hasRelatedWork W1972963040 @default.
• W2335282954 hasRelatedWork W2002032217 @default.
• W2335282954 hasRelatedWork W2542292710 @default.
• W2335282954 hasRelatedWork W2580712355 @default.
• W2335282954 hasRelatedWork W2791421527 @default.
• W2335282954 hasRelatedWork W2793230601 @default.
• W2335282954 hasRelatedWork W4309341410 @default.
• W2335282954 hasRelatedWork W4378902243 @default.
• W2335282954 hasRelatedWork W2340132112 @default.
• W2335282954 hasVolume "38" @default.
• W2335282954 isParatext "false" @default.
• W2335282954 isRetracted "false" @default.
• W2335282954 magId "2335282954" @default.

• next